Genus plc (OTCMKTS:GENSF) Sees Large Growth in Short Interest

Genus plc (OTCMKTS:GENSFGet Free Report) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 37,249 shares, a growth of 633.5% from the January 15th total of 5,078 shares. Based on an average daily volume of 60 shares, the days-to-cover ratio is currently 620.8 days. Based on an average daily volume of 60 shares, the days-to-cover ratio is currently 620.8 days.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Genus in a research note on Thursday, November 20th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

Check Out Our Latest Stock Analysis on Genus

Genus Stock Performance

GENSF remained flat at $37.25 during mid-day trading on Tuesday. The company has a 50 day simple moving average of $35.60 and a 200-day simple moving average of $34.97. Genus has a 52-week low of $35.00 and a 52-week high of $37.25.

About Genus

(Get Free Report)

Genus plc, trading on the OTCMKTS under the symbol GENSF, is a global leader in innovative animal genetics and breeding solutions. The company operates through two primary business segments: ABS and PIC. ABS focuses on bovine genetics, offering dairy and beef cattle semen, advanced reproductive technologies and digital herd management tools. PIC specializes in porcine genetics, providing breeding stock, genetic evaluation services and production support aimed at optimizing growth performance, health and sustainability across the global swine industry.

With origins dating back to its establishment in 1933 as the British Dairy Cattle Breeders’ Society, Genus has expanded through strategic acquisitions and organic growth to build a leading position in animal biotechnology.

See Also

Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.